Artificial Intelligence to Measure Adherence to Oral Medication
ConditionFirst Episode Psychosis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age15-40
SponsorNorthwell Health
About this trial
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
Eligibility criteria
Qualifiers
Enrolled in a CSC program
Prescribed an oral antipsychotic
Disqualifiers
none
Trial design
Treatments tested in this trial
- Smartphone App
- Usual Care
Treatment groups
200 Participants
are divided into 2 treatment groupsLocations
5Citrus Health33012, HialeahFlorida, United States
InterAct49503, Grand RapidsMichigan, United States
InterAct of Michigan49007, KalamazooMichigan, United States
Red Rock73105, Oklahoma CityOklahoma, United States
Sponsors and collaborators
Northwell Health
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov